According to MarketsMOJO, Narayana Hrudayalaya Ltd. has been downgraded from Buy to Hold as of 1 July 2026, with a Mojo Score of 62.0 and current Mojo Grade of Hold. The downgrade reflects a combination of factors including a shift in technical indicators, moderation in valuation appeal, and flat financial performance in the latest quarter. The company's valuation grade has been downgraded from attractive to fair, with the stock currently trading at a price-to-earnings ratio of 46.90, which remains elevated relative to historical averages. The price-to-book value stands at 8.81, and the enterprise value to EBITDA ratio is 26.78, indicating a premium valuation. Comparatively, peers such as Fortis Healthcare and Global Health command even higher valuations, with PE ratios of 67.7 and 62.62 respectively.
According to reports from The Economic Times, Narayana Hrudayalaya Ltd. is demonstrating strong bullish signals after experiencing a recent decline. The hospital stock successfully bounced back after testing the 50-day moving average (50-DMA) on daily charts in June 2026 and subsequently staged a decisive breakout after reclaiming the Ichimoku Cloud. This technical recovery has positioned the stock above its key moving averages, indicating potential momentum for short-term traders. However, recent technical analysis shows mixed signals with weekly indicators like MACD and KST remaining bullish but monthly signals turning mildly bearish. The stock closed at ₹1,958.30 on 1 July 2026, down 0.65% from the previous close of ₹1,971.15, reflecting the current uncertainty in the market.
As reported by MarketsMOJO, the company's Return on Capital Employed (ROCE) stands at a healthy 14.89% for the latest period, supported by a high ROCE of 24.32% over the longer term, indicating effective use of capital to generate profits. Debt servicing capability remains strong with a Debt to EBITDA ratio of 3.62 times, reflecting manageable leverage levels. However, the most recent quarter (Q4 FY25-26) showed flat financial performance with operating profit to interest coverage at a low 5.59 times and a slight increase in debt-equity ratio to 1.29 times. The half-year ROCE dipped to 12.20%, signalling some pressure on returns in the short term. Despite these short-term headwinds, the company's net sales have grown at an annualised rate of 25.05%, while operating profit has surged by 282.56% over the same period, supporting its long-term growth trajectory.
According to MarketsMOJO, the stock's 52-week range remains wide with a high of ₹2,223.00 and a low of ₹1,564.25, underscoring significant volatility. The company has delivered strong long-term returns—310.12% over five years and an impressive 527.86% over ten years, significantly outperforming the Sensex which is down 183.38% over the same period. However, recent performance has been subdued with year-to-date returns at 3.56%, outperforming the Sensex which is down 9.74%, but the one-year return is negative at -6.48%. The company's ROE of 18.79% is respectable but does not fully offset the high multiples, while the PEG ratio of 6.61 suggests that earnings growth is not fully justifying the current price, signalling a stretched valuation. Experts suggest that investors should monitor upcoming quarterly results and technical developments closely, as the stock's long-term track record remains impressive but current market signals favour a more cautious stance.
